Mediwhale
Singapore, Singapore· Est.
AI‑powered retinal imaging platform for early cardiometabolic disease risk assessment and eye‑disease diagnosis.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered retinal imaging platform for early cardiometabolic disease risk assessment and eye‑disease diagnosis.
Cardiovascular DiseaseChronic Kidney DiseaseLiver DiseaseNeurologyOphthalmology
Technology Platform
Retinal imaging combined with deep‑learning algorithms to extract vascular and metabolic biomarkers for systemic disease risk prediction.
Opportunities
FDA clearance for Dr.
Noon CVD would open the large U.S.
preventive screening market; expanding AI models to kidney, liver, and brain disease creates cross‑disciplinary revenue streams.
Risk Factors
Regulatory hurdles across multiple jurisdictions, data‑privacy compliance, and competition from other retinal‑AI platforms could limit adoption.
Competitive Landscape
Key competitors include Google Health, Optomed, and other AI‑driven retinal diagnostics; Mediwhale differentiates through a focus on cardiometabolic risk and a cloud‑native, device‑agnostic SaaS delivery model.